In this cohort study using data from more than 80 000 patients with T2D and established CVD, those with the greatest cost-sharing for SGLT2 inhibitors and GLP-1 RA had a significantly lower likelihood of treatment intensification to a drug class with proven cardiovascular benefits. Here, SLC5A2 is linked to type 2 diabetes mellitus.